Featured Press Releases

Theralogix Introduces Berberine Enhanced Absorption

Theralogix Introduces Berberine Enhanced Absorption

Eden has launched the world’s first compounded GLP-1 prescription gummy, offering a novel and convenient approach to weight management treatment

Eden has launched the world’s first compounded GLP-1 prescription gummy, offering a novel and convenient approach to weight management treatment

  • 31 Dec 2024

Eden has launched the world's first compounded semaglutide gummy. Designed to deliver the benefits of GLP-1...

PharmAbcine

PharmAbcine's Phase 1 Trial of PMC-403 for Neovascular Age-Related Macular Degeneration Advances to Single-Dose (4mg) and Multiple-Dose (3mg)

Nona Biosciences Updates on ADC Collaboration with BeiGene and DualityBio

Nona Biosciences Updates on ADC Collaboration with BeiGene and DualityBio

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

Mytos announces partnerships with StemSight, Rinri Therapeutics, and Novadip to drive next-generation cell therapy trials

Mytos announces partnerships with StemSight, Rinri Therapeutics, and Novadip to drive next-generation cell therapy trials

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

  • Jazz Pharmaceuticals plc
  • 17 Nov 2025
New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

  • Johnson & Johnson
  • 17 Nov 2025
Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

  • Marius Pharmaceuticals LLC
  • 13 Nov 2025
The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

  • Asahi Kasei
  • 13 Nov 2025
Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

  • Odyssey Therapeutics, Inc.
  • 11 Nov 2025
HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

  • HanchorBio Inc.
  • 10 Nov 2025

Most Popular
November   2025
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.